1.Proton magnetic resonance spectroscopy of the thalamus and hypothalamus in patients with first-episode depression.
Rui YANG ; Xiao-ping WU ; Xiao-ying BAI ; Wen-de NING ; Jun-le YANG ; Zhi-chuan XIE
Journal of Southern Medical University 2009;29(12):2442-2445
OBJECTIVETo investigate the presence of abnormal metabolism in the thalamus and hypothalamus in patients with first-episode depression.
METHODSThirty drug-naive patients with first-episode depression and 30 age-matched controls were scanned with proton magnetic resonance spectroscopy ((1)H-MRS) for Naa, Cho, Cr and mI.
RESULTSCompared with the control group, the patients showed significantly reduced mI and mI/Cr of the hypothalamus, reduced mI/Cr of the left thalamus, and lowered Cho, ml, and ml/Cr of the right thalamus (P<0.05).
CONCLUSIONPatients with first-episode depression may have myo-inositol and phosphoric acid metabolism disorder in the thalamus and hypothalamus with malfunction of cellular osmotic pressure adjustment mechanism. Abnormal mI/Cr in the thalamus and hypothalamus may represent an important biochemical change in advanced patients with depression.
Adolescent ; Adult ; Case-Control Studies ; Choline ; metabolism ; Creatine ; metabolism ; Depression ; diagnosis ; Female ; Humans ; Hypothalamus ; metabolism ; Inositol ; metabolism ; Magnetic Resonance Spectroscopy ; methods ; Male ; Middle Aged ; Protons ; Thalamus ; metabolism ; Young Adult
2.Expression and diagnostic value of serum miR-26a/b in patients with gastric cancer
Yiran SI ; Haiyang ZHANG ; Yi WANG ; Ting DENG ; Ming BAI ; Tao NING ; Le ZHANG ; Yi BA
Chinese Journal of Clinical Oncology 2017;44(24):1242-1247
Objective:To discuss the diagnostic value of miR-26a/b and relationship of this microRNA with clinicopathological features in patients with gastric cancer. Methods:The expression of serum miR-26a/b was detected in 121 patients with gastric cancer and 116 healthy controls using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). The relationship of miR-26a/b and clinicopathological parameters of patients were analyzed. The receiver operating curve (ROC) was constructed to in vestigate the value of miR-26a/b in the diagnosis of gastric cancer. Results:The relative expression levels of serum miR-26a and miR-26b in patients with gastric cancer were lower than those in the control group (1.60±1.02 vs. 5.35±0.44;1.44±0.71 vs. 5.35±0.71;P<0.05). The relative expression level of miR-26a/b correlated with TNM stage, and the relative expression level of miR-26a also correlated with invasion depth and lymph node metastasis (P<0.05), but not with sex, age, tumor size, or histological type (P>0.05). The area under the ROC curve of miR-26a was 0.828 (95%CI:0.776~0.881), with sensitivity of 73.3%and specificity of 81.0%, while the area under the ROC curve of miR-26b was 0.853 (95%CI:0. 801~0.906), with sensitivity of 68.1%and specificity of 99.2%. Conclusion:The expression of miR-26a/b significantly reduced in patients with gastric cancer, and its expression level correlated with the clinical stage, invasion depth, and lymph node metastasis. MiR-26a/b has potential diagnostic value for gastric cancer.
3.Consolidating the foundation, highlighting the practice and strengthening the training of clinical thinking of acupuncture and moxibustion: the thoughts of compiling the China national standardized training textbook Acupuncture and Moxibustion for residents of traditional Chinese medicine.
Xue-Si HOU ; Cheng TAN ; Bai-le NING ; Wen-Bin FU ; Ji-Ping ZHAO
Chinese Acupuncture & Moxibustion 2022;42(7):834-838
Based on the clinical needs and examination requirements of standardized training students, the China national standardized training textbook Acupuncture and Moxibustion for residents of traditional Chinese medicine has made innovations in the textbook content and form. In the part of meridians and acupoints, the classic original text is introduced and the main indications and operation methods of 200 commonly-used acupoints are summarized in the form of tables. In the part of acupuncture and moxibustion technique, the operating procedures are standardized and the core technical points of 20 commonly-used acupuncture and moxibustion techniques are summarized in the form of flow chart. In the part of acupuncture and moxibustion treatment, 48 typical diseases are introduced in the form of case discussion, highlighting the problem orientation and demonstrating the diagnosis and treatment procedures.
Acupuncture/education*
;
Acupuncture Therapy
;
China
;
Humans
;
Medicine, Chinese Traditional
;
Moxibustion
4. Determination of Total Polysaccharides in Decoction Pieces of Polyporus with Different Sources and Different Grades
Ning GUO ; Zhi-yong LE ; Wan-wan WANG ; Wei-juan JIA ; Zong-li BAI ; Jian-hua SUN ; Hong WANG
Chinese Journal of Experimental Traditional Medical Formulae 2019;25(5):156-160
Objective: To establish a method for determining the content of total polysaccharides in decoction pieces of Polyporus,analyze the content of total polysaccharides in samples with different sources and grades. Method: The relative molecular weight and the polydispersity index of polysaccharides in decoction pieces of Polyporus were measured by a high performance gel chromatography coupled with a multi-angle laser light scattering and refractive index system.Dextran with similar molecular weight as polysaccharides was selected as the reference substance.Orthogonal experiment and single factor tests were used to optimize the pretreatment conditions for the determination of total polysaccharides in Polyporus.Polysaccharides in Polyporus with different areas and grades were determined by anthrone-sulfuric acid colorimetric method at 630 nm. Result: The linearity,stability,precision,repeatability and recovery rate of the established method all reached the standards,respectively.The content of total polysaccharides in samples from different areas ranged from 0.87% to 1.39%.The content of total polysaccharides in samples with different grades was 1.40% for first-grade pieces,1.21% for second-grade pieces, and 1.03% for third-grade pieces. Conclusion: The established method is simple,accurate and reproducible,and it can be used for the determination of polysaccharides in decoction pieces of Polyporus.The content of polysaccharides in samples from different origins varies greatly.The content of polysaccharides in samples with different grades shows a certain regularity.The content of polysaccharides is the highest in the first-grade pieces,followed by the content in the second-grade,and the lowest in the third-grade.The results can provide a reference for formulating limits for the content of total polysaccharides and the grade standard of decoction pieces of Polyporus.
5.Professor
Wen FU ; Meng-Yu WANG ; Bai-le NING ; Peng ZHOU ; Wen-Bin FU
Chinese Acupuncture & Moxibustion 2021;41(10):1140-1144
The paper summarizes the ideas and characteristics of acupoint selection in treatment of mental disorder with acupuncture and moxibustion by professor
Acupuncture Points
;
Acupuncture Therapy
;
Humans
;
Mental Disorders/therapy*
;
Meridians
;
Moxibustion
6.Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer.
Haiyang ZHANG ; Jingjing DUAN ; Yanjun QU ; Ting DENG ; Rui LIU ; Le ZHANG ; Ming BAI ; Jialu LI ; Tao NING ; Shaohua GE ; Xia WANG ; Zhenzhen WANG ; Qian FAN ; Hongli LI ; Guoguang YING ; Dingzhi HUANG ; Yi BA
Protein & Cell 2016;7(2):141-151
Gastric cancer is one of the most common malignancies worldwide; however, the molecular mechanism in tumorigenesis still needs exploration. BCL2L11 belongs to the BCL-2 family, and acts as a central regulator of the intrinsic apoptotic cascade and mediates cell apoptosis. Although miRNAs have been reported to be involved in each stage of cancer development, the role of miR-24 in GC has not been reported yet. In the present study, miR-24 was found to be up-regulated while the expression of BCL2L11 was inhibited in tumor tissues of GC. Studies from both in vitro and in vivo shown that miR-24 regulates BCL2L11 expression by directly binding with 3'UTR of mRNA, thus promoting cell growth, migration while inhibiting cell apoptosis. Therefore, miR-24 is a novel onco-miRNA that can be potential drug targets for future clinical use.
Animals
;
Apoptosis
;
genetics
;
Apoptosis Regulatory Proteins
;
deficiency
;
genetics
;
Base Sequence
;
Bcl-2-Like Protein 11
;
Cell Line, Tumor
;
Cell Movement
;
genetics
;
Cell Proliferation
;
genetics
;
Down-Regulation
;
genetics
;
Gene Silencing
;
Male
;
Membrane Proteins
;
deficiency
;
genetics
;
Mice
;
MicroRNAs
;
genetics
;
Proto-Oncogene Proteins
;
deficiency
;
genetics
;
Rats
;
Stomach Neoplasms
;
genetics
;
pathology
7.The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study.
Jing Jing DUAN ; Tao NING ; Ming BAI ; Le ZHANG ; Hong Li LI ; Rui LIU ; Shao Hua GE ; Xia WANG ; Yu Chong YANG ; Zhi JI ; Fei Xue WANG ; Yan Sha SUN ; Yi BA ; Ting DENG
Chinese Journal of Oncology 2023;45(11):967-972
Objective: To explore the efficacy of chemotherapy re-challenge in the third-line setting for patients with metastatic colorectal cancer (mCRC) in the real world. Methods: The clinicopathological data, treatment information, recent treatment efficacy, adverse events and survival data of mCRC patients who had disease progression after treatment with oxaliplatin-based and/or irinotecan-based chemotherapy and received third-line chemotherapy re-challenge from January 2013 to December 2020 at Tianjin Medical University Cancer Institute and Hospital were retrospectively collected. Survival curves were plotted with the Kaplan-Meier method, and the Cox proportional hazard model was used to analyze the prognostic factors. Results: A total of 95 mCRC patients were included. Among them, 32 patients (33.7%) received chemotherapy alone and 63 patients (66.3%) received chemotherapy combined with targeted drugs. Eighty-three patients were treated with dual-drug chemotherapy (87.4%), including oxaliplatin re-challenge in 35 patients and irinotecan re-challenge in 48 patients. The remaining 12 patients were treated with triplet chemotherapy regimens (12.6%). Among them, as 5 patients had sequential application of oxaliplatin and irinotecan in front-line treatments, their third-line therapy re-challenged both oxaliplatin and irinotecan; 7 patients only had oxaliplatin prescription before, and these patients re-challenged oxaliplatin in the third-line treatment. The overall response rate (ORR) and disease control rate (DCR) reached 8.6% (8/93) and 61.3% (57/93), respectively. The median progression free survival (mPFS) and median overall survival (mOS) were 4.9 months and 13.0 months, respectively. The most common adverse events were leukopenia (34.7%) and neutropenia (34.7%), followed by gastrointestinal adverse reactions such as nausea (32.6%) and vomiting (31.6%). Grade 3-4 adverse events were mostly hematological toxicity. Cox multivariate analysis showed that gender (HR=1.609, 95% CI: 1.016-2.548) and the PFS of front-line treatments (HR=0.598, 95% CI: 0.378-0.947) were independent prognostic factors. Conclusion: The results suggested that it is safe and effective for mCRC patients to choose third-line chemotherapy re-challenge, especially for patients with a PFS of more than one year in front-line treatments.
Humans
;
Irinotecan/therapeutic use*
;
Oxaliplatin/therapeutic use*
;
Colorectal Neoplasms/pathology*
;
Retrospective Studies
;
Fluorouracil
;
Colonic Neoplasms/chemically induced*
;
Rectal Neoplasms/drug therapy*
;
Antineoplastic Combined Chemotherapy Protocols/adverse effects*
;
Camptothecin/adverse effects*
8.The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study.
Jing Jing DUAN ; Tao NING ; Ming BAI ; Le ZHANG ; Hong Li LI ; Rui LIU ; Shao Hua GE ; Xia WANG ; Yu Chong YANG ; Zhi JI ; Fei Xue WANG ; Yan Sha SUN ; Yi BA ; Ting DENG
Chinese Journal of Oncology 2023;45(11):967-972
Objective: To explore the efficacy of chemotherapy re-challenge in the third-line setting for patients with metastatic colorectal cancer (mCRC) in the real world. Methods: The clinicopathological data, treatment information, recent treatment efficacy, adverse events and survival data of mCRC patients who had disease progression after treatment with oxaliplatin-based and/or irinotecan-based chemotherapy and received third-line chemotherapy re-challenge from January 2013 to December 2020 at Tianjin Medical University Cancer Institute and Hospital were retrospectively collected. Survival curves were plotted with the Kaplan-Meier method, and the Cox proportional hazard model was used to analyze the prognostic factors. Results: A total of 95 mCRC patients were included. Among them, 32 patients (33.7%) received chemotherapy alone and 63 patients (66.3%) received chemotherapy combined with targeted drugs. Eighty-three patients were treated with dual-drug chemotherapy (87.4%), including oxaliplatin re-challenge in 35 patients and irinotecan re-challenge in 48 patients. The remaining 12 patients were treated with triplet chemotherapy regimens (12.6%). Among them, as 5 patients had sequential application of oxaliplatin and irinotecan in front-line treatments, their third-line therapy re-challenged both oxaliplatin and irinotecan; 7 patients only had oxaliplatin prescription before, and these patients re-challenged oxaliplatin in the third-line treatment. The overall response rate (ORR) and disease control rate (DCR) reached 8.6% (8/93) and 61.3% (57/93), respectively. The median progression free survival (mPFS) and median overall survival (mOS) were 4.9 months and 13.0 months, respectively. The most common adverse events were leukopenia (34.7%) and neutropenia (34.7%), followed by gastrointestinal adverse reactions such as nausea (32.6%) and vomiting (31.6%). Grade 3-4 adverse events were mostly hematological toxicity. Cox multivariate analysis showed that gender (HR=1.609, 95% CI: 1.016-2.548) and the PFS of front-line treatments (HR=0.598, 95% CI: 0.378-0.947) were independent prognostic factors. Conclusion: The results suggested that it is safe and effective for mCRC patients to choose third-line chemotherapy re-challenge, especially for patients with a PFS of more than one year in front-line treatments.
Humans
;
Irinotecan/therapeutic use*
;
Oxaliplatin/therapeutic use*
;
Colorectal Neoplasms/pathology*
;
Retrospective Studies
;
Fluorouracil
;
Colonic Neoplasms/chemically induced*
;
Rectal Neoplasms/drug therapy*
;
Antineoplastic Combined Chemotherapy Protocols/adverse effects*
;
Camptothecin/adverse effects*